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INTRODUCTION
With more than 30 therapeutic antibodies approved 
worldwide, therapeutic antibodies have become a major 
category in the pharmaceutical market. In an effort to fur-
ther expand the potential of therapeutic antibodies, several 
approaches are being employed, such as improving the effec-
tor functions of the antibodies, designing antibody-drug 
conjugates, and downsizing the antibody molecule. Among 
these approaches, enhancing antibody-dependent cellular 
cytotoxicity (ADCC), which is the major effector function 
of an antibody, is thought to be one of the most promising 
and practical approaches to make an antibody more 
efficacious. In this “Perspective”, we have provided an over-
view of such ADCC-enhancing technologies, while focusing 
mainly on our Potelligent
Ⓡ Technology, which has been 
most extensively tested in clinical trials.
ADCC AS A MAJOR MODE OF ACTION OF ANTIBODY 
THERAPY
ADCC is a cytolytic effector mechanism by which an 
antigen-specific antibody stimulates immune effector cells, 
primarily NK (natural killer) cells, to kill antigen-expressing 
cells. This process is triggered by the binding of the Fc 
domain of an antibody to the FcγRs (FcγRIIIa in human) 
on NK cells, followed by the activation of NK cells, and 
then, the destruction of target cells. A number of preclinical 
studies have shown that ADCC is a major mechanism of 
action of antitumor antibodies such as rituximab, trastuzu-
mab, and alemtuzumab. Furthermore, the importance of 
ADCC has also been shown by clinical trials, which have 
provided evidence of a significant correlation between 
FcγRIIIa functional polymorphisms and clinical outcomes, 
demonstrated by multiple therapeutic antibodies, including 
rituximab, trastuzumab, cetuximab, and infliximab. Thus, 
ADCC is now considered an important clinical mechanism, 
and enhancing ADCC has become a logical approach to 
improve the efficacy of therapeutic antibodies.
ADCC-ENHANCING TECHNOLOGIES
ADCC can be enhanced in several different ways, one 
of which is the modification of amino acids in the Fc domain. 
Shields et al. have shown that the Fc-domain variants with 
up to 3 mutations improved binding of the Fc domain with 
FcγRIIIa and enhanced the capacity for ADCC [1]. More 
recently, Lazar et al. have utilized computational 3D model-
ing methods to design an IgG1-Fc variant with 3 mutations 
that showed markedly enhanced FcγRIII binding, ADCC, 
and, importantly, B-cell depletion in monkeys by using an 
anti-CD20 system [2].
The other established approach for enhancing ADCC is 
the modification of the oligosaccharide structure in the Fc 
domain. The Fc region of an IgG molecule has 2 N-linked Korean J Hematol 2011;46:148-50.
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Fig. 1. Comparison between conventional and defucosylated antibodies. (A) Comparison of ADCC: In vitro ADCC of conventional (circle) and 
defucosylated (square) rituximab was compared. (B) Comparison of oligosaccharide profile: The percentage of rituximab produced by using 
conventional CHO cells and that produced by the FUT8−/− CHO cells was compared. Fucosylated oligosaccharides were not detected in the
FUT8−/− CHO-produced ritumixab.
glycosylation sites located at N297 (asparagine 297) of the 
2 heavy chains. The N297-linked oligosaccharide chains 
are of the complex biantennary type, which has structural 
heterogeneity in certain moieties, and this heterogeneity 
affects the antibody’s effector functions. While it was know 
that the presence of the terminal sialic acid might affect 
FcγRIIIa binding and ADCC, Umaña et al. have shown that 
increased amount of bisecting GlcNAc (N-acetyl-D-glucos-
amine) adjacent to the core mannose resulted in a 10-fold 
ADCC enhancement [3]. Meanwhile, our group, as well 
as several others, has been focusing on the fucose residue 
for its possible effect on ADCC; these studies eventually 
led to the establishment of the Potelligent
Ⓡ Technology.
POTELLIGENT
Ⓡ TECHNOLOGY
Potelligent
Ⓡ Technology, one of the most potent tech-
nologies for enhancing ADCC, originated from the initial 
discovery that reducing or eliminating fucose from the oligo-
saccharides on the Fc domain significantly increased 
FcγRIIIa binding and dramatically enhanced ADCC by -100 
fold; the impact of this modification was, by far, greater 
than that of any other glycomodifications (Fig. 1A) [4]. 
Intensive studies have shown that a defucosylated antibody 
has a number of desirable features for clinical applications: 
it can induce potent ADCC at a lower dose and antigen 
density than a conventional antibody can [5], and it induces 
more potent in vivo anti-tumor activity than its conven-
tional counterpart in animal models [5]. Additionally, in 
contrast to the antibodies obtained by introducing amino 
acid mutations, an antibody with no fucose is a natural 
component of human serum, and therefore, has a lower 
risk of immunogenicity.
For clinical application of this technology, it was critical 
to establish a robust production system, because all the 
commonly used host cells for biologics manufacturing pro-
duce highly fucosylated proteins. To this end, we generated 
a genetically engineered Chinese hamster ovary (CHO) host 
c e l l  l i n e  t h a t  i s  i n c a p a b l e  o f  a d d i n g  f u c o s e  t o  a n  o l i g o -
saccharide chain; this was achieved by knocking out the 
FUT8 gene, which encodes the only enzyme that catalyzes 
the core fucosylation in mammals [6]. The established 
FUT8−/− CHO cells were confirmed to produce fully defu-
cosylated antibodies (Fig. 1B), with their other basic charac-
teristics being undistinguishable from a wild-type CHO cell, 
thereby making the knockout cell an ideal host for ADCC- 
enhanced antibodies.
CLINICAL APPLICATION OF THE POTELLIGENT
Ⓡ 
TECHNOLOGY
To date, as many as 10 Potelligent
Ⓡ-applied antibodies 
produced by using the FUT8−/− CHO cells have been 
investigated in human clinical trials, and a growing body 
of evidence has now confirmed the clinical benefits of this 
technology. Among those antibodies, the anti-CCR4 anti-
body, KW-0761 (mogamulizumab), is the most advanced. 
In a phase I/II study in patients with relapsed/refractory 
cutaneous T-cell lymphoma, KW-0761 produced an overall 
response rate of 39% with a manageable safety profile [7]. 
In a separate pivotal phase II study in patients with relapsed 
adult T-cell leukemia-lymphoma, a remarkable overall re-
sponse rate of 50% was observed [8]; a new drug application 
for this antibody was filed with the Japanese regulatory 
agency in April 2011.
CONCLUSION
With therapeutic antibodies becoming a major pharma-
ceutical entity, an effort to create next-generation antibodies Korean J Hematol 2011;46:148-50.
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is in full swing. The Potelligent
Ⓡ defucosylation technology 
is among the approaches for creating such engineered anti-
bodies, and it has proven clinically effective. More clinical 
data from multiple antibodies are needed to fully evaluate 
the clinical benefits of this technology.
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